Ischemic Cerebrovascular Disease Clinical Trial
— BPV-NhICVDOfficial title:
Blood Pressure Variability in Non-hypertensive Patients With Ischemic Cerebrovascular Disease
NCT number | NCT05232240 |
Other study ID # | BPV-NhICVD |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | February 14, 2022 |
Est. completion date | February 2028 |
This study is a single-center prospective cohort of patients with ischemic cerebrovascular disease (ICVD) who have not met the diagnostic criteria for hypertension. Ambulatory 24-hour blood pressure monitoring (ABPM) will be performed at baseline and one year after the enrollment. The primary purpose of the study is to delineate the relationship of blood pressure variability (BPV) with the risk of composite vascular events in non-hypertensive patients with ICVD. The factors related to BPV, as well as the potential modulators of the associations between BPV and vascular risk, will be further explored among these patients.
Status | Recruiting |
Enrollment | 300 |
Est. completion date | February 2028 |
Est. primary completion date | February 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Diagnosed as ischemic stroke or transient ischemic attack (TIA), with confirmation of computed tomography or magnetic resonance imaging. 2. Less than 90 days after onset of ischemic stroke or TIA symptoms. 3. The blood pressure measured 5~90 days after the ICVD onset without any anti-hypertension treatment is less than 140/90 mmHg (an average of =2 readings obtained on = 2 occasions after emptying bladder, relaxing for more than 5 min, and avoiding caffeine, exercise, or smoking for at least 30 min before measurement). 4. Consent to participate in the study. Exclusion Criteria: 1. A definite diagnosis of hypertension. 2. Under anti-hypertension treatment. 3. Worsening neurological conditions. 4. With a National Institute of Health Stroke Scale score more than 5 points. 5. Intracranial hemorrhage. 6. Autonomic failure. 7. With malignant tumors or poor organ functions or hematologic diseases, whose estimated life expectancy is less than 3 years. 8. With contraindications to ambulatory 24-hour blood pressure monitoring or fail to finish the examination at baseline. 9. Mental disease. 10. Pregnant. |
Country | Name | City | State |
---|---|---|---|
China | Xuanwu Hospital, Capital Medical University | Beijing | Beijing |
Lead Sponsor | Collaborator |
---|---|
Xuanwu Hospital, Beijing |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 3-year risk of Major Adverse Cardiovascular Event | the time of first documented cardiovascular mortality (any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death), ischemic stroke, myocardial infarction or unstable angina | 3 years | |
Secondary | 90-day Functional Outcome | percentage of patients with modified Rankin Scale (mRS) scores (minimum 0 and maximum 5) 3 to 5, who are considered to be disabled | 90 days | |
Secondary | 1-year rate of Major Adverse Cardiovascular Event | the rate of cardiovascular mortality (any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, and unobserved sudden death), ischemic stroke, myocardial infarction and unstable angina | 1 year | |
Secondary | 1-year rate of Ischemic Stroke | the rate of fatal and nonfatal ischemic stroke | 1 year | |
Secondary | 1-year rate of Acute Coronary Syndrome | the rate of first documented fatal and nonfatal myocardial infarction and unstable angina | 1 year | |
Secondary | 1-year rate of Cardiovascular Mortality | the rate of mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, and unobserved sudden death | 1 year | |
Secondary | 3-year risk of Ischemic Stroke | the time of first documented fatal or nonfatal ischemic stroke | 3 years | |
Secondary | 3-year risk of Acute Coronary Syndrome | the time of first documented fatal or nonfatal myocardial infarction or unstable angina | 3 years | |
Secondary | 3-year risk of Cardiovascular Mortality | the time of mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03589053 -
Limb Remote Ischemic Conditioning and Cerebrovascular Reserve
|
Phase 2 | |
Enrolling by invitation |
NCT01925872 -
Optimal Regimen in Endovascular Therapy in Ischemic Cerebrovascular Disease Based on Clopidogrel Resistance
|
N/A | |
Not yet recruiting |
NCT03153878 -
The Prospective Cohort Study on the Benefit-risk of Antithrombotic or Anticoagulant Therapy in Patients With Unruptured Intracranial Aneurysms Associated With Ischemic Heart Disease or Ischemic Cerebrovascular Disease
|
N/A | |
Completed |
NCT02966418 -
Hypoxic Preconditioning on Patients
|
N/A | |
Not yet recruiting |
NCT06001073 -
Prognosis Prediction System of Patients With Cardiovascular and Cerebrovascular Diseases Based on Multi-omics
|
||
Recruiting |
NCT03794843 -
Bioavailability Comparison Study of Two Types of Nimodipine Injections in Healthy Volunteers
|
Early Phase 1 | |
Not yet recruiting |
NCT05716646 -
In the Real World Study, the Efficacy and Adverse Reactions of Ticagrelor on Ischemic Cerebrovascular Disease
|
||
Recruiting |
NCT03256513 -
The Safety and Efficacy of Peri-procedure Blood Pressure Management of Revascularization
|
N/A |